Obesity
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Communication Preferences
Sign Out
Sign In | Create Account
  • Obesity Home
    • Products
      Obesity Treatments
    • Professional Resources
      Product Resources Library
  • Sample Requests
    • Disease Education
      Obesity: A Chronic Disease
    • Treatment Guidelines
      AACE Obesity Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Library
    • Disease Education
      Disease Education Library
    • Prescription Savings & Coverage
      Savings Cards Coverage Support
    • Support Programs
      Weight-Loss Support
  • Sign In
    Create Account
    • Account Settings
    • Communication Preferences
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Wegovy® (semaglutide) injection 2.4 mg logo
Important Safety Information | Patient Site
Prescribing Information
    • The Impact of Obesity
    • How Weight Loss Can Help
    • Causes of Obesity
    • How Wegovy® Works
    • The Legacy of Semaglutide
    • STEP 1 Results
    • STEP 5 Results
    • STEP 4 Results
    • Cardiometabolic End Points
    • Common Adverse Events
    • Semaglutide Cardiovascular Safety Data
    • The Wegovy® Pen
    • Prescribing Wegovy®
    • Dose-Escalation Schedule
    • Navigating Coverage Eligibility
    • Co-pay Cards
    • For Pharmacists
    • WeGoTogether®
    • Frequently Asked Questions
    • Telehealth
Wegovy® (semaglutide) injection 2.4 mg logo

As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with a BMI of ≥30 kg/m2 (obesity), or ≥27 kg/m2 (overweight) in the presence of a weight-related comorbidity. Click for Limitations of Use.

Prescribing Information
Important Safety Information | Patient Site

We appreciate your interest in Wegovy®. To help answer patient questions about supply, click here.

Click here for important news about chronic weight management for your appropriate patients aged 12-17 with obesity.

Sorry, your browser doesn't support embedded videos.

Actor portrayal of weight loss progression

The first and only once-weekly GLP-1 RA for chronic weight management1

CO-PRIMARY END POINT1,2

~15% weight loss

14.9% mean weight loss vs 2.4% (~6 lb) weight loss with placebo at 68 weeks

Mean baseline body weight: Wegovy®=232.4; placebo=231.9 lb.

Mean baseline BMI: 37.9 kg/m2.

Explore the data

CO-PRIMARY END POINT1,2

~85% of patients

83.5% vs 31.1% of patients with placebo achieved ≥5% weight loss at 68 weeks

Mean baseline body weight: Wegovy®=232.4 lb; placebo=231.9 lb.

Mean baseline BMI: 37.9 kg/m2.

Get the full trial results

SUPPORTIVE SECONDARY END POINT1-3†

~1 out of 3 patients taking Wegovy® (30.2%) vs 1.7% of patients with placebo achieved ≥20% (≥~46 lb) weight loss at
 68 weeks

Weight loss in pounds (lb) calculated as 20% of mean baseline body weight of Wegovy® and placebo patients.

Explore the data

†Supportive secondary end points were not included in the statistical testing hierarchy and, as such, not controlled for multiplicity. These data are from the cumulative frequency distribution for change in body weight.

Study design

STEP 1: A 68-week placebo-controlled study of 1,961 adults randomized 2:1 to receive Wegovy® or placebo; patients in both arms received instruction for a reduced-calorie diet and increased physical activity. During the trial, 17% of patients in the Wegovy® arm discontinued treatment compared with 22% in the placebo arm.1,2

BMI, body mass index; GLP-1 RA, glucagon-like peptide-1 receptor agonist.
*At 68 weeks.

Find out about coverage options for your patients

Let's go
Let's go
Wegovy™ Pen icon

Discover the once-weekly Wegovy® pen

Learn more
Once Weekly

Get familiar with the Wegovy® dose escalation

See the schedule

Join the Wegovy® Informational Messaging System (WIMS) to learn more about Wegovy® straight from your phone

Text CHANGE to 54178 to join‡

‡Message frequency varies. Message and data rates may apply. To review Terms and Conditions, click here.

Important Safety Information for Wegovy® (semaglutide) injection 2.4 mg

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
  • Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy® and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy®

Indication and Usage

Wegovy® (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

Limitations of Use

  • Wegovy® contains semaglutide and should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist
  • The safety and effectiveness of Wegovy® in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established
  • Wegovy® has not been studied in patients with a history of pancreatitis


Important Safety Information cont.

Contraindications

  • Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy®. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with semaglutide

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy® in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy® promptly, and if acute pancreatitis is confirmed, do not restart
  • Acute Gallbladder Disease: In clinical trials, cholelithiasis was reported by 1.6% of Wegovy® patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy® patients and 0.2% of placebo patients. Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in Wegovy®-treated patients than in placebo-treated patients, even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Hypoglycemia: Wegovy® lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy® patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy® with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes
  • Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy® in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion
  • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with semaglutide. If hypersensitivity reactions occur, discontinue use of Wegovy®, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist
  • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: In a trial of patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy® patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
  • Heart Rate Increase: Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy® patients compared to placebo in clinical trials. More Wegovy® patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy®
  • Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy® in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation

Adverse Reactions

  • The most common adverse reactions reported in ≥5% of patients treated with Wegovy® are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease

Drug Interactions

  • The addition of Wegovy® in patients treated with insulin has not been evaluated. When initiating Wegovy®, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
  • Wegovy® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy®

Use in Specific Populations

  • Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue Wegovy®. Discontinue Wegovy® in patients at least 2 months before a planned pregnancy

Please click here for Wegovy® Prescribing Information, including Boxed Warning.

References

1. Wegovy® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2021.

2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.

3. Data on file. Novo Nordisk, Inc.; Plainsboro, NJ.

 

Obesity
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Obesity Home
  • Product Information
    Products
    • Obesity Treatments
    Professional Resources
    • Product Resources Library
  • Sample Requests
  • Professional Education
    Disease Education
    • Obesity: A Chronic Disease
    Treatment Guidelines
    • AACE Obesity Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Library
    Disease Education
    • Disease Education Library
    Prescription Savings & Coverage
    • Savings Cards
      Coverage Support
    Support Programs
    • Weight-Loss Support

novoMEDLINK™ is a trademark of Novo Nordisk A/S.

Wegovy® and WeGoTogether® are registered trademarks of Novo Nordisk A/S.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

This website is intended for US Health Care Professionals.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved. US22SEMO00212 December 2022

Quick links

Request medication samples

Obesity treatment guidelines

Patient savings card offer

Patient support program